Toxicity and cosmesis following partial breast irradiation consisting of 40 Gy in 10 daily fractions |
| |
| Authors: | Marco Trovo Mario Roncadin Jerry Polesel Erica Piccoli Mario Mileto Elvia Micheli Tiziana Perin Antonino Carbone Samuele Massarut Mauro G. Trovo |
| |
| Affiliation: | 1. Department of Radiation Oncology, Centro di Riferimento Oncologico of Aviano, via F. Gallini 2, 33081 Aviano (PN), Italy;2. Department of Epidemiology and Biostatistics, Centro di Riferimento Oncologico of Aviano, Italy;3. Department of Surgery, Centro di Riferimento Oncologico of Aviano, Italy;4. Department of Surgery, Pordenone General Hospital, Italy;5. Department of Pathology, Centro di Riferimento Oncologico of Aviano, Italy;1. Department of Academic Oncology, The Royal Free Hampstead NHS Trust, Pond Street, London NW3 2QG, UK;2. Sussex Health Outcomes Research and Education in Cancer (SHORE-C), Brighton and Sussex Medical School, Brighton BN1 9RX, UK;3. Clinical Trials Research Unit, University of Leeds, Leeds LS2 9JT, UK;4. Breast Unit, Charing Cross Hospital, Imperial Healthcare Trust, London W6 8RF, UK;5. Department of Radiation Physics and Radiobiology, Charing Cross Hospital, London W6 8RF, UK;6. Department of Surgery and Cancer, MRC Cyclotron Building, Faculty of Medicine, Imperial College London, Du Cane Road, London W12 ONN, UK;1. Department of Surgery, Breast Unit, General University Hospital Elche, Alicante, Spain;2. Department of Nursery, Breast Unit, General University Hospital Elche, Alicante, Spain;3. Department of Surgical Nursery, Hospital del Sureste, Madrid, Spain;4. Department of Surgery, Hospital de Hellin, Albacete, Spain;1. Department of Surgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Republic of Korea;2. Biostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul, Republic of Korea;3. Department of Radiology, Yonsei University College of Medicine, Seoul, Republic of Korea;4. Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea;1. Department of Surgery, The Queen Elizabeth Hospital, South Australia, Australia;2. BreastSurgANZ Quality Audit, Australian Safety and Efficacy Register of New Interventional Procedures – Surgical (ASERNIP-S), Royal Australasian College of Surgeons, North Adelaide, Australia;3. Melanoma Institute of Australia, Breast & Oncology Centre, North Sydney, New South Wales, Australia;4. Department of Surgery, Royal Adelaide Hospital, South Australia, Australia;5. Mater Hospital, Department of Surgery, South Brisbane, Queensland, Australia;6. Waikato Clinical School, University of Auckland, Faculty of Medical and Health Sciences, Auckland, New Zealand;7. National Quality Audit, Australian Safety and Efficacy Register of New Interventional Procedures – Surgical (ASERNIP-S), Royal Australasian College of Surgeons, North Adelaide, Australia;1. Clinical and Experimental Pathology, Research Center Borstel, Parkallee 3a, 23845 Borstel, Germany;2. Clinical Center Itzehoe, Gyneacological Hospital, Holsteinisches Breast Center, Itzehoe, Germany;3. imland Clinic Rendsburg, Pathology, Holsteinisches Breast Center Rendsburg, Germany;4. imland Clinic Rendsburg, Gyneacological Hospital, Holsteinisches Breast Center, Rendsburg, Germany;5. University Medical Center Hamburg Eppendorf, Pathology, Hamburg, Germany |
| |
| Abstract: | PurposeTo assess the toxicity and cosmetic results in breast cancer patients undergoing adjuvant partial breast irradiation (PBI) to a total dose of 40 Gy in 10 daily fractions (4 Gy/fraction).Methods and materialsPatients affected by early-stage breast cancer were enrolled in this phase II trial. Patients had to be 60 years old and treated with breast conservative surgery for early stage (pT1–T2 pN0–N1a) invasive ductal carcinoma.Results77 patients were enrolled. Median follow-up was 18 months. The proposed schedule was well tolerated. One patient reported Grade 3 pain at the site of irradiation. Four (5%) patients experience Grade 2 erythema. Late Grade 2 and 1 fibrosis was observed in 3 (4%) and 14 (18%) patients, respectively. Cosmesis was judged “good/excellent” and “poor” in 75 (97%) and in 2 (3%) patients, respectively.Conclusions40 Gy in 10 daily fractions, 4 Gy/fraction, is a well tolerated regimen to deliver PBI. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
